Trial Profile
A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jun 2023
Price :
$35
*
At a glance
- Drugs Eptinezumab (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms PROMISE 1
- Sponsors Alder Biopharmaceuticals
- 27 Apr 2023 Results from PROMISE-1 and PROMISE-2 ; demonstrating the lack of a wearing off effect with eptinezumab in preventive migraine treatment, presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 10 Dec 2022 Results of a post-hoc analysis from two clinical studies (PROMISE-1 and PROMISE-2) assessing proportions of patients shifting from higher to lower levels of headache frequency over Months 1-6 of treatment presented at the 16th European headache federation COngress
- 12 Jun 2022 Results of a post-hoc analysis assessing proportions of patients shifting from higher levels of headache/migraine frequency to lower levels over the first 6 months of treatment.from two clinical studies: PROMISE-1 and PROMISE-2 presented at the 64th Annual Scientific Meeting of the American Headache Society